No Data
No Data
Goldman Sachs: Buy rating on CSPC Pharma with a target price of HK$10.03.
Goldman Sachs released a research report stating a 'buy' rating for CSPC Pharma (01093), with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 BD trades within 2024, and emphasizes continuous review of product lines, strengthening business expansion efforts. The bank expects more trades to occur in the future. It was mentioned that CSPC Pharma plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein (a) in the preclinical stage) and any products containing YS2302018 global rights. The company's first collaboration with AstraZeneca is seen by the bank as a global expansion for the company.
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AstraZeneca Deal Has Positive Read for Silence Therapeutics, Says Morgan Stanley
Another old pharmaceutical company has successfully transformed through innovation.
Intensive product BD, heavyweight personnel appointments, 5 billion repurchase plan, cspc pharma's stock price surged more than 60% in three weeks.
AstraZeneca's Phase III Trial of Treatment for Asthma Meets Its Primary Endpoint
No Data
No Data